Factors Associated With Antipsychotic Polypharmacy and High-Dose Antipsychotics Among Individuals Receiving Compulsory Treatment in the Community

被引:10
|
作者
Gisev, Natasa [1 ]
Bell, J. Simon [2 ,3 ,4 ]
Chen, Timothy F. [1 ]
机构
[1] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[2] Monash Univ, Ctr Med Use & Safety, Fac Pharm & Pharmaceut Sci, Parkville, Vic, Australia
[3] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland
[4] Univ S Australia, Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
关键词
antipsychotic agents; commitment of mentally ill; community mental health services; drug utilization; logistic models; LONG-ACTING INJECTIONS; TREATMENT ORDERS; SCHIZOPHRENIA; CLOZAPINE; DRUGS; AUGMENTATION; TOLERABILITY; PREVALENCE; KNOWLEDGE; ATTITUDES;
D O I
10.1097/JCP.0000000000000098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Community treatment orders (CTOs) are a form of compulsory treatment of individuals with a mental illness in the community. The objectives of this study were to determine the demographic, clinical, and treatment plan factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with a CTO. This was a secondary analysis of all 377 individuals who were prescribed an antipsychotic, extracted from a retrospective study of 378 individuals issued with a CTO by the New South Wales Mental Health Review Tribunal in Australia in 2009. Deidentified information relating to individuals' treatment plans, demographic, and clinical details were systematically extracted. Of the 377 individuals, 121 (32%) were prescribed antipsychotic polypharmacy and 101 (27%) high-dose antipsychotics. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for factors associated with antipsychotic polypharmacy and high-dose antipsychotics were computed using binary logistic regression. There was a strong association between the use of antipsychotic polypharmacy and high-dose antipsychotics (P < 0.001). Only treatment plan factors were associated with antipsychotic polypharmacy and high-dose antipsychotics in adjusted models. Although first-generation long-acting injectable antipsychotics and clozapine were associated with antipsychotic polypharmacy (adjusted OR, 9.12; 95% CI, 4.21-19.74; adjusted OR, 7.97; 95% CI, 2.93-21.72), oral second-generation antipsychotics and risperidone long-acting injection were associated with high-dose antipsychotics (adjusted OR, 5.67; 95% CI, 2.89-11.12; adjusted OR, 8.14; 95% CI, 3.22-20.53). Therefore, the use of antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with CTOs is associated only with the drugs prescribed in their treatment plans and not their individual demographic and clinical characteristics.
引用
下载
收藏
页码:307 / 312
页数:6
相关论文
共 50 条
  • [31] Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment
    Levine, JE
    Cohen, A
    MacQueen, M
    Martin, M
    Giardina, PJ
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (02) : 139 - 141
  • [32] Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease
    Koponen, Marjaana
    Taipale, Heidi
    Lavikainen, Piia
    Tanskanen, Antti
    Tiihonen, Jari
    Tolppanen, Anna-Maija
    Ahonen, Riitta
    Hartikainen, Sirpa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 363 - 363
  • [33] Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease
    Koponen, Marjaana
    Taipale, Heidi
    Lavikainen, Piia
    Tanskanen, Antti
    Tiihonen, Jari
    Tolppanen, Anna-Maija
    Ahonen, Riitta
    Hartikainen, Sirpa
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 56 (01) : 107 - 118
  • [34] POLYPHARMACY AND ASSOCIATED FACTORS AMONG COMMUNITY-DWELLING OLDER PERSONS IN A SWISS CANTON
    Fustinoni, S.
    Renard, D.
    Santos-Eggimann, B.
    Seematter-Bagnoud, L.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E39 - E39
  • [35] Risk factors associated with high-dose methotrexate induced toxicities
    Li, Wenshu
    Mo, Jiayi
    Yang, Zhilin
    Zhao, Zhigang
    Mei, Shenghui
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 263 - 274
  • [36] Antipsychotic polypharmacy and associated factors among patients with schizophrenia: Multicenter cross-sectional study in Northwest Ethiopia
    Tamene, Fasil Bayafers
    Sema, Faisel Dula
    Sendekie, Ashenafi Kibret
    PLOS ONE, 2023, 18 (08):
  • [37] Factors Associated With Receiving Rapid HIV Testing Among Individuals on Probation or Parole
    Gordon, Michael S.
    Carswell, Steven B.
    Wilson, Monique
    Kinlock, Timothy W.
    Restivo, Lauren
    McKenzie, Michelle
    Rich, Josiah D.
    JOURNAL OF CORRECTIONAL HEALTH CARE, 2016, 22 (04) : 290 - 299
  • [38] RISK FACTORS OF DELAYED METHOTREXATE ELIMINATION AFTER RECEIVING HIGH-DOSE METHOTREXATE THERAPY
    Liang, C. A.
    VALUE IN HEALTH, 2023, 26 (06) : S191 - S191
  • [39] A Factor Analysis of Patients' Views of Compulsory Community Treatment Orders: The Factors Associated with Detention
    Newton-Howes, Giles
    PSYCHIATRY PSYCHOLOGY AND LAW, 2013, 20 (04) : 519 - 526
  • [40] Association between community pharmacy loyalty and persistence and implementation of antipsychotic treatment among individuals with schizophrenia
    Zongo, Frank E.
    Moisan, Jocelyne
    Gregoire, Jean-Pierre
    Lesage, Alain
    Dossa, Anara Richi
    Lauzier, Sophie
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2018, 14 (01): : 53 - 61